Another Israeli exit in the biotech sector. Clinical research firm Amarin agreed to acquire Israel-based privately held research and development company Ester Neurosciences for an initial $15m (€10.2m), in addition to $17m (€11.5m) in contingent payments.
Ester Neurosciences Ltd. is a development stage biopharmaceutical company committed to the discovery and development of novel therapeutic products for the treatment of neurological disorders such as myasthenia gravis, Alzheimer’s disease, multiple sclerosis and acute stress reactions. Ester’s unique platform technology is based on the company’s breakthrough discoveries relating to cholinergic neuromodulation and its involvement in the diseased state. Ester was led by Prof. Eli Hazum, and founded in 1997. [via]
I'm a former general partner at google ventures, head of Google for Entrepreneurs in Europe and founding head of Campus London, Google's first physical hub for startups.
I'm also the founder of Techbikers, a non-profit bringing together the startup ecosystem on cycling challenges in support of Room to Read. Since inception in 2012 we've built 11 schools and 50 libraries in the developing world.
- Breaking the mold: Pattern Breakers book review - November 18, 2024
- Weekly Firgun Newsletter – November 15 2024 - November 15, 2024
- Kindling Early B2C Growth: Getting to 1,000 Users - November 11, 2024
